A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Oral Psilocybin (TRP-8802) Administration in Concert With Psychotherapy Among Adult Patients With Irritable Bowel Syndrome: A Randomized Delayed Treatment Control Design
Latest Information Update: 09 Feb 2026
At a glance
- Drugs Psilocybin (Primary)
- Indications Abdominal pain
- Focus Adverse reactions
- Sponsors Entropy Neurodynamics
Most Recent Events
- 05 Feb 2026 Status changed from recruiting to active, no longer recruiting.
- 08 Sep 2025 Planned End Date changed from 1 Feb 2025 to 1 Mar 2026.
- 08 Sep 2025 Planned primary completion date changed from 1 Feb 2025 to 1 Mar 2026.